News & Trends - Pharmaceuticals
Sanofi raises the bar for employee benefits, seeing the person as a whole individual
Among all chronic conditions, individuals diagnosed with cancer face the highest prevalence of employment loss. In this Health Industry Hub interview, Michelle Zimany, People Business Partner Lead for Specialty Care in the Japan Pacific region at Sanofi, delved into the critical intersection of employment and cancer diagnosis, and a first-of-its-kind program raising the bar for employee benefits in the healthcare industry.
“50% of individuals diagnosed with cancer are afraid to tell their workplace. This is despite 92% saying that their workplace plays a critical role in how they’re feeling about their health, particularly mentally,” she explained.
The inception of Sanofi’s Cancer & Work global program stemmed from an inspiring employee initiative in 2017. Ms Zimany shared a story of a Sanofian who was the driving force behind the initiative, choosing to “fight to live her life. Not just to survive, but really to continue to do the things that gave her meaning and purpose.”
When asked about the tangible benefits of the Cancer & Work program for employees locally, she emphasised its role in offering a holistic approach, ranging from peer support, flexible work arrangements and salary protection for a year.
“We’ve had some people who are in remission say that if the Cancer & Work program had been available when they were diagnosed, it would have changed their whole outlook on how they approached work,” she shared.
The launch of the Cancer & Work program aligns seamlessly with Sanofi’s short- and long-term Diversity, Equity, and Inclusion (DE&I) strategy.
“Our vision is to reflect the diversity of our communities and ensure that we’re enabling people to unleash their full potential in order to transform healthcare,” she stated.
In closing, Ms Zimany offered invaluable advice to organisations contemplating similar programs. She stressed the importance of “really looking within your own organisation to help accelerate great ideas” and to “go slow in order to go fast”.
In reimagining healthcare, Health Industry HubTM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News & Trends - MedTech & Diagnostics
APAC medtech company scores TGA approval in heart disease
MedTech & Diagnostics News: An Asia Pacific medtech company has announced that its flagship drug-eluting stent (DES) has received regulatory […]
MoreNews & Trends - MedTech & Diagnostics
New state-based pilot to back home-grown medtech innovation
MedTech & Diagnostics: In a bid to enhance opportunities for local medtech manufacturers to sell to health services, a connected […]
MoreNews & Trends - Pharmaceuticals
Ferring unveils first real-world evidence for faecal calprotectin approach in ulcerative colitis
Pharma News: Ferring Pharmaceuticals has announced results from a new study, which provides the first real-world evidence supporting the efficacy […]
MoreNews & Trends - Pharmaceuticals
Bayer partners with RACGP, calls for MBS reforms to boost access to long-acting contraceptives
Pharma News: Australian women are calling for more accurate information about their contraceptive options, with 70% feeling inadequately educated about […]
More